ReportWire

Tag: Columbia University Irving Medical Center

  • Columbia University Launches Center for Precision Psychiatry & Mental Health with $75 Million Grant from the Stavros Niarchos Foundation (SNF)

    Columbia University Launches Center for Precision Psychiatry & Mental Health with $75 Million Grant from the Stavros Niarchos Foundation (SNF)

    [ad_1]

    Newswise — NEW YORK, April 24, 2023—Columbia University today announced the establishment of the Stavros Niarchos Foundation (SNF) Center for Precision Psychiatry & Mental Health at Columbia University. The center will catalyze the scientific innovation and clinical implementation of precision medicine to advance the prevention, diagnosis, and treatment of mental illness. The center is being established with a $75 million grant from the Stavros Niarchos Foundation (SNF), an international philanthropic organization, as part of SNF’s Global Health Initiative (GHI). 

    The SNF Center is a joint effort of the Department of Psychiatry at Columbia University Vagelos College of Physicians and Surgeons and Columbia’s Zuckerman Mind Brain Behavior Institute. It will be embedded within Columbia University’s unique ecosystem of research and clinical services and will draw upon expertise from the Columbia-affiliated New York Genome Center and the New York State Office of Mental Health.

    The increasing sophistication of precision medicine is allowing scientists and health care providers to integrate each person’s unique genomic, physiologic, and health profiles to create optimized prevention and treatment strategies. Columbia University has been at the forefront of recent efforts to elucidate the genetic and biological changes that cause a multitude of severe mental illnesses. The SNF Center for Precision Psychiatry & Mental Health will build upon and expand this knowledge by accumulating massive datasets of genomic sequences and longitudinal medical records.  At the same time, by harnessing interdisciplinary expertise from biologists to clinicians, the center will enable the rapid advent, from bench to bedside, of new therapeutic and prevention approaches based upon defined etiologies shared by distinct subgroups of patients.

    “The insights provided by genomics and precision medicine are proving of tremendous value in improving people’s health and lives,” said Columbia University President Lee C. Bollinger. “Through this new center, our researchers will meet an urgent human need by harnessing precision medicine to promote mental health for all. We are enormously grateful to the Stavros Niarchos Foundation for joining with Columbia in meeting this profound scientific and humanitarian challenge.”

    “The significant progress we have made in caring for our physical health in recent decades is apparent, but just as clear is the fact that we have left behind our mental health,” said SNF Co-President Andreas Dracopoulos. “All of us at SNF are proud to support the doctors, scientists, and mental health professionals at Columbia in bringing together deep expertise with an equally deep sense of humanity to address one of the most critical issues of our time.”

    The collaboration between Columbia and SNF arose from a joint vision for helping to reduce the individual and societal toll of mental illness and to combat social inequality, stigma, and discrimination in mental health care. The ecosystem of knowledge and practice at Columbia University brings together research and clinical services and connects the public and private sectors. By driving innovation in mental health research and sharing advances as widely as possible, Columbia and SNF will work to help ensure that improved treatments are equally available to everyone. 

    “Many existing treatments in psychiatry do not get at root causes,” said Katrina Armstrong, MD, Chief Executive Officer of Columbia University Irving Medical Center and Dean of the Faculties of Health Sciences at the Vagelos College of Physicians and Surgeons. “We welcome this opportunity to develop new approaches that focus on disease mechanisms and target treatment based on an individual’s unique genetic makeup and biology for the ultimate benefit of lifting up care for the community at large.”

    Among the major projects of the SNF Center is the Genomic Medicine for Mental Health Advancement (GeMMA) initiative, being conducted in close collaboration with the New York Genome Center (NYGC). Tom Maniatis, PhD, Evnin Family Scientific Director and CEO of the NYGC and Isidore Edelman Professor of Biochemistry and Molecular Biophysics at Columbia, said, “The GeMMA initiative will not only provide essential information for individual patients, it will also build upon and expand pioneering work at Columbia University central to establishing ‘causal’ relationships between genetic variation and brain function, which is a critical step in the development of new approaches to diagnosis, treatment, and prevention of mental illness.”

    The New York State Office of Mental Health (OMH) is a major partner of the SNF Center with a renowned reputation as one of the largest and most innovative learning public mental healthcare systems in the nation. OMH Commissioner Ann Sullivan, MD said, “The Stavros Niarchos Foundation Center for Precision Psychiatry & Mental Health ushers in an entirely new era of mental health care through the unprecedented potential for integration of precision psychiatry into standard clinical practice. OMH is proud to partner with Columbia University on this transformative mission, and we are deeply grateful to SNF for their remarkable commitment to improving mental health worldwide.”

    The center will be co-directed by Sander Markx, MD, assistant professor of clinical psychiatry at Columbia’s Vagelos College of Physicians and Surgeons (VP&S) and director of the Center for Precision Neuropsychiatry at the New York State Psychiatric Institute; Steven A. Kushner, MD, PhD, professor of psychiatry at VP&S and a principal investigator at the New York State Psychiatric Institute; and Joseph Gogos, MD, PhD, professor of physiology & cellular biophysics, neuroscience, and psychiatry at VP&S and a principal investigator at Columbia’s Zuckerman Mind Brain Behavior Institute, who together conveyed their collective vision for the center: “With this extraordinary support from SNF, we are poised to build on the accelerating progress in psychiatric genomics, neuroscience, artificial intelligence, and stem cell biology to revolutionize the treatment of mental illness. Through this new understanding, we are fundamentally committed to helping combat stigma and discrimination against people living with mental illness and realizing improved mental health care for all.”

     

    About the Stavros Niarchos Foundation (SNF)

    The Stavros Niarchos Foundation (SNF) is one of the world’s leading private, international philanthropic organizations, making grants to nonprofit organizations in the areas of arts and culture, education, health and sports, and social welfare. SNF funds organizations and projects worldwide that aim to achieve a broad, lasting, and positive impact for society at large, and exhibit strong leadership and sound management. The Foundation also supports projects that facilitate the formation of public-private partnerships as an effective means for serving the public welfare. 

    Since 1996, the Foundation has committed over $3.5 billion through more than 5,200 grants to nonprofit organizations in over 130 countries around the world. The ongoing $750 million-plus Global Health Initiative (GHI) is SNF’s largest-ever grant initiative. It includes the design, construction and outfitting of three new hospitals in Greece, procurement of critical equipment such as air ambulances, training programs for health care providers, efforts to expand access to quality mental health care such as the Child and Adolescent Mental Health Initiative in Greece, and collaborations with institutions like The Rockefeller University, the Child Mind Institute, and the National Children’s Alliance in the United States; Sant Joan de Déu Barcelona Children’s Hospital; King Hussein Cancer Foundation and Center in Jordan; and Yorkshire Cancer Research in the United Kingdom.

    See more at snf.org.

     

    About Columbia University

    Among the world’s leading research universities, Columbia University in the City of New York continually seeks to advance the frontiers of scholarship and foster a campus community deeply engaged in understanding and confronting the complex issues of our time through teaching, research, patient care and public service. The Department of Psychiatry at Columbia University Vagelos College of Physicians and Surgeons is among the top-ranked psychiatry departments in the nation and has made major contributions to the understanding and treatment of psychiatric disorders. For almost a century, the department has collaborated with the New York State Office of Mental Health’s Psychiatric Institute, an international leader in understanding mental health and mental illness. Columbia is also home to the Zuckerman Institute, a renowned neuroscience research center that pioneers urgently needed insights into mind, brain and behavior that benefit health and society.

    ####

    [ad_2]

    Columbia University Irving Medical Center

    Source link

  • Spinal Cord Injury: Can Brain and Nerve Stimulation Restore Movement?

    Spinal Cord Injury: Can Brain and Nerve Stimulation Restore Movement?

    [ad_1]

    Newswise — NEW YORK, NY–A nerve stimulation therapy developed at Columbia University Vagelos College of Physicians and Surgeons is showing promise in animal studies and may eventually allow people with spinal cord injuries to regain function of their arms.

    “The stimulation technique targets the nervous system connections spared by injury,” says Jason Carmel, MD, PhD, a neurologist at Columbia University and NewYork-Presbyterian who is leading the research, “enabling them to take over some of the lost function.”

    The findings were published in December in the journal Brain.

    A personal quest to develop treatments for people with paralysis

    In 1999, when Carmel was a second-year medical student at Columbia, his identical twin brother suffered a spinal cord injury, paralyzing him from the chest down and limiting the use of his hands.

    Carmel’s life changed that day, too. His brother’s injury ultimately led Carmel to become a neurologist and a neuroscientist, with the goal of developing new treatments to restore movement in people living with paralysis.

    In recent years, some high-profile studies of spinal cord electrical stimulation have allowed a few people with incomplete paralysis to begin to stand and take steps again.

    Carmel’s approach is different because it targets the arm and hand and because it pairs brain and spinal cord stimulation, with electrical stimulation of the brain followed by stimulation of the spinal cord. “When the two signals converge at the level of the spinal cord, within about 10 milliseconds of each other, we get the strongest effect,” he says, “and the combination appears to enable the remaining connections in the spinal cord to take control.”

    In his latest study, Carmel tested his technique—called spinal cord associative plasticity (SCAP)—on rats with moderate spinal cord injuries. Ten days after injury, the rats were randomized to receive 30 minutes of SCAP for 10 days or sham stimulation. At the end of the study period, rats that received SCAP targeted to their arms were significantly better at handling food, compared to those in the control group, and had near-normal reflexes.

    “The improvements in both function and physiology persisted for as long as they were measured, up to 50 days,” Carmel says.

    The findings suggest that SCAP causes the synapses (connections between neurons) or the neurons themselves to undergo lasting change. “The paired signals essentially mimic the normal sensory-motor integration that needs to come together to perform skilled movement,” says Carmel. 

    From mice to people

    If the same technique works in people with spinal cord injuries, patients could regain something else they lost in the injury: independence. Many spinal cord stimulation studies focus on walking, but “if you ask people with cervical spinal cord injury, which is the majority, what movement they want to get back, they say hand and arm function,” Carmel says. “Hand and arm function allows people to be more independent, like moving from a bed to a wheelchair or dressing and feeding themselves.”

    Carmel is now testing SCAP on spinal cord injury patients at Columbia, Weill Cornell, and the VA Bronx Healthcare System in a clinical trial sponsored by the National Institute of Neurological Disorders and Stroke. The stimulation will be done either during a clinically indicated surgery or noninvasively, using magnetic stimulation of brain and stimulation of the skin on the front and back of the neck. Both techniques are routinely performed in clinical settings and are known to be safe.

    In the trial, the researchers hope to learn more about how SCAP works and how the timing and strength of the signals affect motor responses in the fingers and hands. This would lay the groundwork for future trials to test the technique’s ability to meaningfully improve hand and arm function.

    Looking farther ahead, the researchers think that the approach could be used to improve movement and sensation in patients with lower-body paralysis.

    In the meantime, Jason Carmel’s twin is working, married, and raising twins of his own. “He has a full life, but I’m hoping we can get more function back for him and other people with similar injuries,” says Carmel.

     

    More information

    The study is titled “Spinal cord associative plasticity improves forelimb sensorimotor function after cervical injury.”

    Other contributors: Ajay Pal, HongGeun Park, Aditya Ramamurthy, Ahmet S. Asan, Thelma Bethea, and Meenu Johnkutty (all at Columbia).

    The study was funded by the National Institute of Neurological Disorders and Stroke (R01NS115470) and the Travis Roy Foundation.

    Jason Carmel is a co-inventor of a patent for the use of softening spinal electrodes. He also has equity in Backstop Neural, which seeks to commercialize the devices for humans. The authors declare no other competing financial interests.

    ###

    Columbia University Irving Medical Center

    Columbia University Irving Medical Center (CUIMC) is a clinical, research, and educational campus located in New York City, and is one of the oldest academic medical centers in the United States. CUIMC is home to four professional colleges and schools (Vagelos College of Physicians and Surgeons, Mailman School of Public Health, College of Dental Medicine, and School of Nursing) that are global leaders in their fields. CUIMC is committed to providing inclusive and equitable health and medical education, scientific research, and patient care, and working together with our local upper Manhattan community—one of New York City’s most diverse neighborhoods. For more information, please visit cuimc.columbia.edu.  

     

    [ad_2]

    Columbia University Irving Medical Center

    Source link